Risk of Adverse Events After Anti-TNF Treatment for Inflammatory Rheumatological Disease. A Meta-Analysis

• Autori principali: Ju Li (Autore), Zhongyuan Zhang (Autore), Xinhua Wu (Autore), Jie Zhou (Autore), Deqian Meng (Autore), Ping Zhu (Autore)
• Natura: Libro
• Pubblicazione: Frontiers Media S.A., 2021-11-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Background: Adalimumab, golimumab, infliximab, certolizumab, and etanercept are five anti-tumor necrosis factor (anti-TNF) medicines that have been approved for use in rheumatology. Apart from their well-established therapeutic usefulness, -it is unclear to what extent -they are linked to an increas...